Omentin-1 vs Noopept
Head-to-head comparison of Omentin-1 (Omentin-1 (Intelectin-1, ITLN1)) and Noopept (N-phenylacetyl-L-prolylglycine ethyl ester) — benefits, dosing, side effects, research data, and where to buy.
| Property | Omentin-1 | Noopept |
|---|---|---|
| Category | Diabetes & Metabolic | Cognitive Enhancement |
| Full Name | Omentin-1 (Intelectin-1, ITLN1) | N-phenylacetyl-L-prolylglycine ethyl ester |
| Molecular Weight | ~35 kDa | 318.37 Da |
| Half-Life | hours | 20-30 minutes |
| Amino Acids | 313 | N/A |
| Typical Dose | No approved human dose; research use only | 10-30 mg/day |
| Route | IV|SC | Oral |
| Purity | ≥98% | ≥98% |
| Studies Count | 82 | 60 |
| Research Status | Pre-clinical | Clinical |
Omentin-1 Benefits
- ✓insulin sensitivity
- ✓glucose uptake
- ✓lipid handling
Noopept Benefits
- ✓memory recall
- ✓learning efficiency
- ✓attention support
- ✓neurotrophic signaling
Omentin-1 Dosing
not established|not established
Noopept Dosing
oral research use|10-30 mg per day in human studies|divided or single daily dosing
Omentin-1 Side Effects
- ⚠unknown
- ⚠immunogenicity risk
Noopept Side Effects
- ⚠headache
- ⚠irritability
- ⚠sleep disturbance
Research Overview
Omentin-1
Lower omentin-1 levels are often associated with obesity, insulin resistance, and metabolic syndrome. Research continues on its use as a biomarker and as a mechanistic lead for AMPK-linked metabolic interventions.
Noopept
Noopept has been reported to increase NGF/BDNF-related signaling and improve performance in tasks involving learning and recall. Evidence includes preclinical studies and small human studies, but the overall literature is still modest compared with mainstream cognitive drugs.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.